Koers Avalanche Biotechnologies Inc Nasdaq
Aandelen
US05337G1076
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 314K 292K | Omzet 2025 * | 8,87 mln. 8,24 mln. | Marktkapitalisatie | 216 mln. 201 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -115 mln. -107 mln. | Nettowinst (verlies) 2025 * | -140 mln. -130 mln. | EV/omzet 2024 * | 216 x |
Nettoliquiditeiten 2024 * | 149 mln. 138 mln. | Nettoliquiditeiten 2025 * | 136 mln. 126 mln. | EV/omzet 2025 * | 9,13 x |
K/w-verhouding 2024 * |
-1,9
x | K/w-verhouding 2025 * |
-1,94
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,64% |
Recentste transcriptie over Avalanche Biotechnologies Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Laurent Fischer
CEO | Chief Executive Officer | 60 | 15-06-20 |
Linda Rubinstein
DFI | Director of Finance/CFO | 58 | 12-12-22 |
Bill Tan
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 64 | 16-04-20 | |
Clarence Machado
CHM | Chairman | 60 | 14-03-17 |
Laurent Fischer
CEO | Chief Executive Officer | 60 | 15-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |